AtheroNova initiates phase I clinical trial of AHRO-001

Wednesday, July 3, 2013

AtheroNova, a biotech company focused on the R&D of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, has initiated a phase I clinical trial with its compound, AHRO-001, to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with licensing partner OOO CardioNova.

[Read More]